Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065672 | 0.87 | PLK1 (1.00) | PLK1PLK3 | |
| SCHEMBL5058239 | 0.87 | PLK1 (1.00) | PLK1PLK3 | |
| SCHEMBL4040799 | 0.86 | PLK1 (0.87) | PLK1PLK3 | |
| SCHEMBL5058230 | 0.86 | PLK1 (0.87) | PLK1PLK3 | |
| SCHEMBL6041492 | 0.85 | PLK1 (0.82) | PLK1PLK3 | |
| SCHEMBL4034949 | 0.84 | PLK1 (1.00) | PLK1PLK3 | |
| SCHEMBL5062746 | 0.83 | PLK1 (1.00) | PLK1PLK3 | |
| SCHEMBL4034868 | 0.82 | PLK1 (0.75) | PLK1PLK3 | |
| SCHEMBL5058253 | 0.81 | PLK1 (0.82) | PLK1PLK3 | |
| Gsk-312948A SCHEMBL4037298 | 0.81 | PLK1 (1.00) | PLK1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074119-A1 | Thiophene compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | claimed |
| US-7465807-B2 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465807-B2 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20060074119-A1 | Thiophene compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | disclosed |
| EP-1546137-A1 | BENZIMIDAZOL-1-YL-THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | SmithKline Beecham Corporation (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014899-A1 | THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | CYP3A4, TPMT, TYMP | PLK1 193/4885PLK3 1161/4885 |
| US-20060074119-A1 | Thiophene compounds | TPMT, ABCB1, CYP3A5 | PLK1 2123/4885PLK3 3731/4885 |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ABCB1, TP53, CCNI | PLK1 130/4885PLK3 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.